Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: omalizumab
BRAND NAME: Xolair
DRUG CLASS AND MECHANISM: Omalizumab is an injectable drug that is used for treating asthma. Omalizumab is a protein that resembles one type of human antibody. Antibodies are proteins produced by the body that recognize foreign substances such as bacteria (that cause infection) and pollens (that cause allergies). Once they recognize a foreign substance, the antibodies attach to receptors on two types of cells in tissues and blood, mast cells and basophils. These cells then release chemicals that cause an allergic reaction that leads to inflammation. Omalizumab blocks the receptors on the surfaces of the mast cells and basophils to which antibodies attach, thereby preventing antibodies from attaching to the cells. As a result, the cells do not release their chemicals, and the allergic reaction and inflammation are prevented. In asthmatic individuals, allergic reactions often cause attacks of asthma. Omalizumab reduces the attacks of asthma by preventing the allergic reactions caused by foreign substances. Omalizumab was approved by the FDA in June 2003.
GENERIC AVAILABLE: No PREPARATIONS: Sterile powder for Injection: 5 ml vial (150 mg)
STORAGE: Omalizumab should be refrigerated between 2 C to 8 C (36 F to 46 F). When mixed with sterile water, the solution should be used within 8 hours if refrigerated between 2 C to8 C (36 F to 46 F) or within 4 hours if stored at room temperature.
PRESCRIBED FOR: Omalizumab is used for treating adolescents and adults 12 years and older who have allergy sensitive, moderate to severe persistent asthma, that is not adequately controlled with inhaled steroids.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions